FOGHORN® THERAPEUTICS

CORPORATE OVERVIEW

Leveraging unique insights into the chromatin regulatory system to pioneer a new class of precision therapies in oncology and beyond

January 2023

FORWARD LOOKING STATEMENTS

This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning: the potential outcomes from our collaboration agreements with Lilly and Merck; the initiation, timing, progress and results of our research and development programs and preclinical and clinical trials, including the potential resolution of the full clinical hold and anticipated timing of release of clinical data; our ability to advance product candidates that we may develop and to successfully complete preclinical and clinical studies; our ability to leverage our initial programs to develop additional product candidates using our Gene Traffic Control Platform; the impact of the COVID-19 pandemic and other exogeneous factors on our and our collaborators’ business operations, including our research and development programs and preclinical studies; developments related to our competitors and our industry; our ability to expand the target populations of our programs and the availability of patients for clinical testing; our ability to obtain regulatory approval for FHD-286, FHD-609 and any future product candidates from the FDA and other regulatory authorities; our ability to identify and enter into future license agreements and collaborations; our ability to continue to rely on our CDMOs and CROs for our manufacturing and research needs; regulatory developments in the United States and foreign countries; our ability to attract and retain key scientific and management personnel; the scope of protection we are able to establish, maintain and enforce for intellectual property rights covering FHD-286 and FHD-609, our future products and our Gene Traffic Control Platform; and our use of proceeds from capital-raising transactions, estimates of our expenses, capital requirements and needs for additional financing. Any forward-looking statements represent the Company’s views only as of today and should not be relied upon as representing its views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements. The Company’s business is subject to substantial risks and uncertainties.

FIRST-IN-CLASS PRECISION MEDICINES TARGETING MAJOR UNMET NEEDS IN CANCER

LEADER IN NEW AREA OF CANCER BIOLOGY

Foghorn is a **leader in targeting chromatin biology,** which has unique potential to address underlying dependencies of many genetically defined cancers

Broad pipeline of **over 15 programs** across a range of targets and modalities

LARGE MARKET POTENTIAL

Chromatin biology is implicated in up to **50% of tumors**, potentially impacting **~2.5 million patients**

Foghorn's current pipeline potentially addresses **more than 500,000** of these patients

WELL-FUNDED

$374.5 million in cash and equivalents

(as of 9/30/2022)

Provides **runway into H2'2025**

SIGNIFICANT VALUE DRIVERS IN 2023

Initial clinical data in uveal melanoma with **FHD-286** expected **H1'23**

Initial clinical data in synovial sarcoma with **FHD-609** expected **mid-2023**

AML/MDS study with FHD-286 on full clinical hold, development **clarity anticipated in H1'23**

COLLABORATIONS WITH MAJOR ONCOLOGY PLAYERS

Strategic collaboration with Loxo Oncology at Lilly; **$380 million upfront;** 50/50 U.S. economic split on two lead programs

Merck collaboration to drug single specified transcription factor target; **$15 million upfront** and up to **$410 million** in milestones

FOGHORN: SIGNIFICANT VALUE CREATION OPPORTUNITIES

Potential Impact in >500K Patients Across More Than 20 Tumor Types with 6 Potential New INDs by 2026

- Validated platform with first-in-class targets in the clinic (FHD-286 and FHD-609), with Phase 1 dose escalation data expected in H1 2023 for FHD-286 and mid-2023 for FHD-609
- At least **6** additional potential NME **INDs** by 2026
- **>20** genetically defined tumor types in **over 500K** patients – includes lung, prostate, bladder, ovarian, colorectal, breast
- Opportunity for additional partnerships



UNIQUE INSIGHTS INTO CHROMATIN BIOLOGY

Untapped Area for Novel Targets and Therapeutics

CHROMATIN REGULATORY SYSTEM CRITICAL FOR GENE EXPRESSION

Chromatin – compacted form of DNA inside the nucleus of the cell

Chromatin Remodeling Complex – specialized multiprotein machineries that allow access to DNA



Transcription Factor – proteins that help turn specific genes "on" or "off" by working in concert with the chromatin remodeling complex to bind to DNA

NOVEL TARGETS GUIDED BY GENETIC DEPENDENCIES

Chromatin Remodeling Complex Mutations / Overexpression



Transcription Factor Mutations / Overexpression

Helicases & Other Chromatin Binding Proteins involved in gene expression / function



TAILORED DRUGGING APPROACHES



Enzymatic Inhibitors
Highly selective and allosteric small molecule inhibitors

Targeted Protein Degradation
Molecular glue and bi-functional protein degraders



Transcription Factor Disruptors
Disrupt interactions between chromatin remodeling complexes and transcription factors



FOGHORN'S VALIDATED GENE TRAFFIC CONTROL® PLATFORM

Integrated, Scalable, Efficient – Repeatable Paradigm



UNIQUE TARGETS

Deep Mechanistic Understanding of the Chromatin Regulatory System

What to Drug:

Identify disease dependencies



SPECIALIZED APPROACH

Biochemistry, Biophysics and Assays of Large Complexes and Proteins

Where to Drug:

Engineer selectivity via unique assays and protein capabilities

SELECTIVE THERAPEUTICS

Small Molecule and Degrader Platform

How to Drug:

Biology first - small molecule modality agnostic

Enzymatic Inhibitors	Targeted Protein Degraders	Transcription Factor Disruptors

BROAD PIPELINE ACROSS A RANGE OF TARGETS AND MODALITIES

Precision Oncology / Breadth and Depth / Over 15 Programs



* Incidence in the U.S., EU5, Japan

Inhibition of the BRG1 and BRM Subunits of the BAF Complex

IN PHASE 1 DOSE ESCALATION FOR METASTATIC UVEAL MELANOMA & AML/MDS

FHD-286 is a Potent, Selective, Allosteric, Small Molecule Inhibitor of the BRG1 and BRM Subunits of the BAF Complex

TARGETING BAF DEPENDENCY IN CANCER

BAF CHROMATIN REMODELING COMPLEX



- BRM / BRG1 is the engine (ATPase) of the BAF chromatin remodeling complex
- Dependency on BRM / BRG1 is **well-established with multiple tumor types,** including uveal melanoma, AML / MDS, NSCLC and prostate
- Foghorn's lead asset targeting BRM / BRG1, **FHD-286, is a potent, selective, allosteric, small molecule inhibitor of the BRG1 and BRM subunits** of the BAF complex
- In Phase 1 dose escalation for uveal melanoma & AML / MDS

SIGNIFICANT UNMET NEED IN UVEAL MELANOMA

Most Common Form of Eye Cancer



UVEAL MELANOMA OVERVIEW

Market Opportunity:

- Over 2,500 new metastatic UM patients impacted per year in the U.S. / over 5,000 U.S. and E.U.
- Potential additional opportunity in the adjuvant and neo-adjuvant settings

Limited Treatment Options:

- Treatment options include enucleation, checkpoint inhibitors, KIMMTRAK and chemotherapy/radiation
- KIMMTRAK is indicated for HLA-A2+ haplotype (~40% of the metastatic patient population)

FHD-286 FOR METASTATIC UVEAL MELANOMA

Clinical Development Plan

PHASE 1 DOSE ESCALATION STUDY

- 3+3 cohort design
- Retrospective biomarker analysis to further evaluate safety and efficacy
- Assess safety, PK, biomarkers and therapeutic activity
- Identify dose(s) for expansion

PHASE 1 EXPANSION STUDIES

- Evaluate identified dose(s)
- Consider refined patient population, if necessary
- Consider exploration of combination partners
- Assess safety, PK, biomarkers and therapeutic activity

POTENTIAL DEFINITIVE EFFICACY TRIALS & INDICATION EXPANSION

- Potential for entry into definitive efficacy trials in metastatic UM
- Potential for indication expansion

Initial clinical data in uveal melanoma with FHD-286 expected H1’23

THERAPEUTIC RATIONALE FOR UVEAL MELANOMA

Dependency on Two Lineage Transcription Factors: MITF / SOX10

BIOLOGY

OVER 85% OF UVEAL MELANOMA CANCERS HAVE GNAQ OR GNA11 MUTATIONS



VALIDATION OF DEPENDENCY AND APPROACH









DMSO Control
BRG1/BRM Tool Cmpd

DOSE-DEPENDENT TUMOR REGRESSION IN UVEAL MELANOMA CDX MODELS AT TOLERATED DOSES WITH FHD-286

MP-46 UVEAL MELANOMA CDX MODEL

Dose-dependent tumor growth inhibition

Well-tolerated





92-1 UVEAL MELANOMA CDX MODEL

Dose-dependent tumor growth inhibition

Tumor regression at 1.5 mg / kg, PO, QD

Well-tolerated





Vehicle FHD-286, 0.5 mg/kg, PO, QD FHD-286, 1.5 mg/kg, PO, QD

SIGNIFICANT UNMET NEED REMAINS IN R/R AML & MDS

Most Common Type of Acute Leukemia in Adults

AML MARKET

Relapsed and/or refractory AML patients per year



AML OVERVIEW

Mutation:

- Elevated BRG1-BAF / TF activity in AML blast cells

Market Opportunity:

- Over 27,000 relapsed and/or refractory patients impacted per year*

Treatment Options:

- Limited options for relapsed and/or refractory patients without actionable mutations

* Incidence in the U.S., EU5, Japan

FHD-286 FOR RELAPSED/REFRACTORY AML & MDS

Clinical Development Plan

PHASE 1 DOSE ESCALATION STUDY

- 3+3 cohort design
- Retrospective biomarker analysis to further evaluate safety and efficacy
- Assess safety, PK, biomarkers and therapeutic activity
- Identify dose(s) for expansion

PHASE 1 EXPANSION STUDIES

- Evaluate identified dose(s)
- Consider refined patient population if necessary
- Consider exploration of combination partners
- Assess safety, PK, biomarkers and therapeutic activity

POTENTIAL DEFINITIVE EFFICACY TRIALS & INDICATION EXPANSION

- Potential for entry into definitive efficacy trials in AML / MDS
- Potential for indication expansion

AML / MDS study with FHD-286 on full clinical hold, development clarity anticipated in H1'23

AML: DEPENDENCY ON BRG1 / LINEAGE TF INTERACTIONS

DISEASE STATE



HSC

AML blasts stuck in BAF / TF dependent proliferative phase

Cancerous blast cells rely on BRG1 containing BAF / TF activity



TREATMENT WITH FHD-286





FHD-286 SHOWS EFFECT ACROSS A BROAD RANGE OF MUTATIONS IN AML PATIENT-DERIVED SAMPLES



PRECLINICAL FHD-286 DATA SHOWS EFFICACY ACROSS AML PATIENT-DERIVED SAMPLES

Notable Patient ID	Deep Response	Pathology Review	Disease Status
1690AML1	Y	AML	Secondary
1695AML1	Y	AML/MDS	Secondary
1696AML1	Y	AML	Secondary
1701AML1	Y	AML	Secondary
1893AML1	Y	AML	R/R
1899AML1	Y	AML	R/R
1990pAML1	Y	AML	R/R
1991pAML1	Y	AML	de novo
2041AML1	Y	N/A	de novo
2043pAML1	Y	AML	R/R
2059AML1	Y	AML	R/R
1682AML1	~	N/A	N/A
1689AML1	~	AML/MDS	de novo
1684AML1	N	CML	R/R
1924AML1	N	AML/MDS	R/R

Y = Deep reduction in blast cells ~ = Partial reduction N = No response



- Response observed in a majority of primary AML samples, irrespective of prior treatment or disease stage
- Additional data set from patient-derived samples demonstrates mutation-agnostic responses

DOSE-DEPENDENT TUMOR GROWTH INHIBITION OBSERVED WITH FHD-286 TREATMENT IN AML CDX MODELS

MV4-11 CDX Model
(FLT3 ITD, MLL-AF4)





OCI-AML2 CDX MODEL
(MII-AF6, DNMT3A MUT.)





TUMOR GROWTH INHIBITION WITH FHD-286 TREATMENT OBSERVED BY BIOLUMINESCENCE

Imaging in a Disseminated AML Model

VEHICLE



FHD-286 1.5 MG / KG, BID (5ON / 8OFF) X3



FHD-286 1.5 MG / KG QDX28



SORAFENIB 15 MG / KG, QDX14



FHD-286 SURVIVAL ADVANTAGE IN DISSEMINATED AML MODEL



Degrading the BRD9 Subunit of the BAF Complex

IN PHASE 1 DOSE ESCALATION FOR SYNOVIAL SARCOMA AND SMARCB1-LOSS TUMORS

FHD-609 is a Selective, Potent, Protein Degrader of the BRD9 Component of the BAF Complex

DEGRADING THE BRD9 SUBUNIT OF BAF

BRD9 IS REQUIRED FOR THE SURVIVAL OF SYNOVIAL SARCOMA CELLS



CANCER CELL LINES
Project DRIVE shRNA data

- Dependency on BRD9 **well established with multiple tumor types** including synovial sarcoma and SMARCB1-loss tumors
- Foghorn's lead asset targeting BRD9, **FHD-609, s**elective, potent, protein degrader **of the BRD9 subunit** of the BAF complex
- In Phase 1 dose escalation for synovial sarcoma and SMARCB1-loss tumors

* U.S., EU5, Japan

SIGNIFICANT UNMET NEED IN SYNOVIAL SARCOMA

Synovial Sarcoma Accounts for ~10% of Soft-Tissue Sarcoma Tumors



TARGETED PROTEIN DEGRADATION TO REGULATE CHROMATIN AND GENE EXPRESSION IN DISEASE

SYNOVIAL SARCOMA & SMARCB1-LOSS TUMORS OVERVIEW

- **Mutation**: 100% of patients harbor SS18-SSX1 / SSX2 / SSX4 protein fusions
- **Patient Numbers***:
  - Synovial sarcoma: Over 1,800
  - SMARCB1-Loss Tumors: ~1,000
- **Limited Treatment Options**:
  - No approved therapies
  - Current standard of care includes surgical resection, chemotherapy/radiation and pazopanib
  - Adaptimmune's cell therapy in development for synovial sarcoma, only applicable to ~25% of patient population

* Incidence in the U.S., EU5, Japan

FHD-609 FOR METASTATIC SYNOVIAL SARCOMA AND SMARCB1-LOSS TUMORS

Clinical Development Plan

PHASE 1 DOSE ESCALATION STUDY

- 3+3 cohort design
- Assess safety, PK, therapeutic activity, target engagement and biomarkers
- Identify dose(s) for expansion
- Biomarkers: SS18-SSX1, SS18-SSX2 or SS18-SSX4 translocation for synovial sarcoma

PHASE 1 EXPANSION STUDIES

- Metastatic synovial sarcoma expansion cohorts
- SMARCB-1 deleted tumors and potentially other indications
- Evaluate identified dose(s)
- Consider refined patient population if necessary
- Consider exploration of combination partners
- Assess safety, PK, biomarkers and therapeutic activity

POTENTIAL DEFINITIVE EFFICACY TRIALS & INDICATION EXPANSION

- Potential for entry into definitive efficacy trials in metastatic synovial sarcoma
- Potential for indication expansion beyond metastatic synovial sarcoma

Initial clinical data in synovial sarcoma with FHD-609 expected mid-2023

ON-TREATMENT TUMOR BIOPSIES WITH FHD-609 DEMONSTRATE TARGET ENGAGEMENT WITH DEGRADATION OF BRD9

SIGNIFICANT BRD9 DEGRADATION OF ~60-70% WITH LOW DOSE OF FHD-609

Paired Biopsies Patient A

Pre-Treatment



On-Treatment



Paired Biopsies Patient B

Pre-Treatment



On-Treatment



ROBUST *IN VIVO* ACTIVITY OBSERVED IN SYNOVIAL SARCOMA MODEL AND BRD9 DEGRADATION ASSOCIATED WITH FHD-609 TREATMENT

Weekly Dosing of FHD-609 Achieved Sustained BRD9 Degradation

SY01 SYNOVIAL SARCOMA CDX MODEL

- Mutation: **SS18-SSX2**
- Inhibited tumor growth
- Dose-dependent BRD9 degradation correlated with anti-tumor activity



SUSTAINED BRD9 DEGRADATION



SUPERIOR TUMOR GROWTH INHIBITION WITH FHD-609 IN A SYNOVIAL SARCOMA MODEL AS COMPARED TO IFOSFAMIDE AND PAZOPANIB

ASKA CDX MODEL

- Mutation: **SS18-SSX1**
- Superior tumor growth inhibition compared to ifosfamide and pazopanib
- Complete suppression observed over 30 days at 2 mg / kg of FHD-609



FHD-609 IS HIGHLY SELECTIVE

No Off-Target IMiD Neosubstrate Degradation Activity Observed

KINETIC DEGRADATION PROFILING



ENDPOINT DEGRADATION PROFILING



FHD-609 SELECTIVELY DEGRADES BRD9 IN SYNOVIAL SARCOMA GLOBAL PROTEOMICS ANALYSES

BRD9 Is the Only Protein Significantly Degraded at Multiple Concentrations and Time Points

16nM (200x DC50) 4hrs in SYO1



78nM (1000x DC50) 4hrs in SYO1



16nM (200x DC50) 24hrs in SYO1



SELECTIVE BRM MODULATORS

FOR BRG1 MUTATED CANCERS

Enzymatic Inhibitor and Protein Degrader Programs Targeting BRG1 Mutated Cancers (e.g., NSCLC), 30+ Cancers with BRG1 Mutations

BRG1 MUTATIONS CREATE A GENETIC DEPENDENCY ON BRM

Selective BRM Modulators Overview

Target / Approach	• BRM • Enzymatic inhibitor • Targeted protein degrader
Indications	• BRG1 mutated cancers (e.g., NSCLC), 30+ cancers with BRG1 mutations
Mutation / Aberration	• BRG1
Stage	• Pre-clinical
New Patients Impacted / Year*	• > 100,000
Economics of Lilly Collaboration	• 50/50 U.S. economics • Tiered ex-U.S. royalties starting in the low double-digit range and escalating into the twenties





* Per year incidence in U.S., EU5, Japan

BRG1 MUTATED IN ~5% OF ALL TUMORS

Broad Addressable Patient Population

BRG1 MUTATED ACROSS RANGE OF TUMORS



BRG1 MUTATED IN UP TO 10% OF NSCLC TUMORS, MINIMAL OVERLAP WITH OTHER MUTATIONS

BRM SELECTIVE INHIBITOR *IN VIVO* EFFICACY

Demonstrates PK / PD and *In Vivo* Efficacy in a BRG1 Mutant Lung CDX Model

A549-BRG1 MUTANT NSCLC MODEL



Body Weight





- Vehicle Control (BID)
- Cisplatin 4 mg / kg (IP)
- FHT-BRMi 15 mg / kg (BID)
- FHT-BRMi 30 mg / kg (BID)

ENZYMATIC SELECTIVITY APPROACHING 200X ACHIEVED



ADVANCING BRM SELECTIVE DEGRADERS

Achieving Complete BRM Degradation

BRM / BRG1 HIBIT DATA



A549 TEN-DAY PROLIFERATION ASSAY



DEGRADERS CAUSE TIME- AND DOSE-DEPENDENT BRM DEGRADATION, ANTIPROLIFERATIVE EFFECTS IN A549 BRG1 MUTANT NSCLC LUNG MODEL

FOGHORN THERAPEUTICS

SELECTIVE CBP PROTEIN DEGRADER

FOR EP300 MUTATED CANCERS

Implicated in Subsets of Cancers Including Bladder, Colorectal, Breast, Gastric and Lung

ADVANCING HIGHLY SELECTIVE CBP PROTEIN DEGRADER FOR EP300 MUTATED CANCERS

Selective CBP Protein Degrader Overview

Target / Approach	• CREB binding protein (CBP) • Targeted protein degrader
Initial Indication	• EP300 mutated cancers (e.g., subsets of prostate, bladder, colorectal, breast, gastric and lung cancers)
Mutation / Aberration	• EP300 mutated cancers
Stage	• Pre-clinical
New Patients Impacted / Year*	• Over 100,000



* Per year incidence in U.S., EU5, Japan

ADVANCEMENT OF HIGHLY SELECTIVE CBP DEGRADERS

SELECTIVE CBP DEGRADATION
Osteosarcoma Cell Line

Selective CBP Degrader
U2OS



Endogenous IF

HiBiT-CBP
U2OS



Dmax: 88%

HiBiT-EP300
U2OS



HIGHLY SELECTIVE DEGRADER OF CBP DEMONSTRTES CBP-DEPENDENT CELL KILLING ACROSS MULTIPLE CANCERS

Gastric Cancer



Colorectal Cancer



Bladder Cancer



CELL PROLIFERATION ASSAYS

FOGHORN THERAPEUTICS

SELECTIVE ARID1B PROTEIN DEGRADER

FOR ARID1A MUTATED CANCERS

Protein Degrader Targeting ARID1A Mutated Cancers, the Most Mutated Subunit in the BAF Complex
(e.g., Ovarian, Endometrial, Colorectal, Bladder and Other Cancers)

ARID1A: MOST MUTATED SUBUNIT IN BAF COMPLEX – CREATES DEPENDENCY ON ARID1B

Selective ARID1B Protein Degrader Overview

Target / Approach	• ARID1B • Targeted protein degrader
Initial Indication	• ARID1A mutated cancers
Mutation / Aberration	• ARID1A mutations (e.g., ovarian, endometrial, colorectal, bladder and other cancers)
Stage	• Pre-clinical
New Patients Impacted / Year*	• > 175,000





* Per year incidence in U.S., EU5, Japan

ARID1A MUTATED CANCERS: SIGNIFICANT OPPORTUNITY

ARID1A Mutated Across Range of Tumors





~5% of all solid tumors harbor ARID1A mutations

Hodges et al. 2017

TARGETING ARID1A MUTATED CANCERS: ARID1B PROTEIN DEGRADER

Advantaged by Gene Traffic Control Platform and Protein Degrader Capabilities

GENE TRAFFIC CONTROL PLATFORM

- Platform produces BAF complexes and subcomplexes containing either ARID1A or ARID1B at scale
- Enables proprietary screens against ARID1B

PROTEIN DEGRADER CAPABILITIES

- Utilize protein degrader toolbox to create ARID1B hetero-bifunctional degraders

PROGRAM STATUS

- Validated selective chemical binders of ARID1B
- In process of expanding binders into novel selective protein degraders
- Assessing outcomes of ARID1B degradation and impact on BAF complex formation



Highly purified ARID1B / BAF complex



FOGHORN THERAPEUTICS

TRANSCRIPTION FACTORS

A NOVEL APPROACH

A NEW APPROACH TO DRUGGING TRANSCRIPTION FACTORS

Enabled by Proprietary Ability to Purify and Synthesize Chromatin Regulatory System Components

TFS ARE COMPELLING DRUG TARGETS…

- Highly involved in gene expression
- Implicated in range of cancers and other diseases

…BUT HISTORICALLY DIFFICULT TO TARGET

- Featureless surface: no druggable binding pocket
- Tight interactions with DNA: undruggable affinities

FOGHORN HAS A NEW APPROACH FOCUSING ON INTERACTION WITH BAF

- Druggable binding pockets
- Druggable affinities

FOGHORN'S FOCUS



TRANSCRIPTION FACTORS BIND TO BAF DIRECTLY WITH HIGH DEGREE OF SPECIFICITY

Unique Insights into Where and How Transcription Factors Bind



MAPPING THE TF-BAF INTERACTION



MASS SPEC. FOOT-PRINTING



PULL-DOWN ASSAYS

Foghorn's collection of BAF sub-complexes and domains

VALIDATING THE TF-BAF INTERACTION

BIOPHYSICAL

AUC / SPR / ITC



BIOCHEMICAL

TR-FRET / FP

STRUCTURAL

Crystal / NMR



HIGHLY SCALABLE APPROACH TO ADDRESS SIGNIFICANT UNMET MEDICAL NEED DRIVES MERCK COLLABORATION

Potential to Drug > 100 TFs Associated with BAF

TRANSCRIPTION FACTOR DISRUPTORS



- >100 TFs estimated associated with BAF
- Foghorn pursuing multiple TFs in parallel
- Approach highly scalable and potential broad application – other chromatin remodeling complexes and other diseases

MERCK

- Merck collaboration to drug single specified transcription factor target
- $15 million upfront; up to $410 million in research, development, regulatory and sales-based milestones
- Up to low double-digit royalties on product sales

BROAD PIPELINE ACROSS A RANGE OF TARGETS AND MODALITIES

Precision Oncology / Breadth and Depth / Over 15 Programs



* Incidence in the U.S., EU5, Japan

FIRST-IN-CLASS PRECISION MEDICINES TARGETING MAJOR UNMET NEEDS IN CANCER

LEADER IN NEW AREA OF CANCER BIOLOGY

Foghorn is a **leader in targeting chromatin biology,** which has unique potential to address underlying dependencies of many genetically defined cancers

Broad pipeline of **over 15 programs** across a range of targets and modalities

LARGE MARKET POTENTIAL

Chromatin biology is implicated in up to **50% of tumors**, potentially impacting **~2.5 million patients**

Foghorn's current pipeline potentially addresses **more than 500,000** of these patients

WELL-FUNDED

$374.5 million in cash and equivalents

(as of 9/30/2022)

Provides **runway into H2'2025**

SIGNIFICANT VALUE DRIVERS IN 2023

Initial clinical data in uveal melanoma with **FHD-286** expected **H1'23**

Initial clinical data in synovial sarcoma with **FHD-609** expected **mid-2023**

AML/MDS study with FHD-286 on full clinical hold, development **clarity anticipated in H1'23**

COLLABORATIONS WITH MAJOR ONCOLOGY PLAYERS

Strategic collaboration with Loxo Oncology at Lilly; **$380 million upfront;** 50/50 U.S. economic split on two lead programs

Merck collaboration to drug single specified transcription factor target; **$15 million upfront** and up to **$410 million** in milestones

APPENDIX

FOGHORN THERAPEUTICS

STRATEGIC PARTNERSHIP

LOXO ONCOLOGY AT LILLY

STRATEGIC COLLABORATION WITH LOXO ONCOLOGY AT LILLY

Foghorn to Lead Discovery and Research Activities

$380 MILLION UPFRONT

$300 million cash payment

$80 million investment in Foghorn common stock at a price of $20 per share

50/50 U.S. ECONOMICS ON TWO PROGRAMS

50/50 U.S. economic split on BRM-Selective and another undisclosed program

Tiered ex-U.S. royalties starting in the low double-digit range and escalating into the twenties based on revenue levels

THREE UNDISCLOSED DISCOVERY PROGRAMS

Option to participate in a percentage of the U.S. economics

Tiered ex-U.S. royalties from the mid-single digit to low-double digit range

$1.3 billion in potential milestones

THE CHROMATIN REGULATORY SYSTEM

ORCHESTRATES GENE EXPRESSION

THE CHROMATIN REGULATORY SYSTEM ORCHESTRATES GENE EXPRESSION

Two Major Components Work in Concert: Chromatin Remodeling Complexes and Transcription Factors



CHROMATIN

Chromatin – compacted form of DNA inside the nucleus of the cell

1 | CHROMATIN REMODELING COMPLEX AND TRANSCRIPTION FACTOR

Work together to orchestrate gene expression





2 | RIGHT GENES

TFs guide chromatin remodeling complexes to the right locations

3 | NORMAL GENE EXPRESSION

Once chromatin is unpacked, gene expression can occur



BREAKDOWNS IN THE CHROMATIN REGULATORY SYSTEM CAN LEAD TO DISEASE



Abnormal Gene Expression

DISEASE

Mutation or overexpression in chromatin remodeling complex results in abnormal gene expression

Mutated or overexpressed TF hijacks chromatin remodeling complex to wrong location



Abnormal Gene Expression

DISEASE

CHROMATIN REGULATORY SYSTEM

Abundance of Targets within the BAF Complex

BAF COMPLEX AND ASSOCIATED TRANSCRIPTION FACTORS



28 Chromatin Remodeling Complexes and >1,000 TFs

BAF Complex Subunits Mutated and Dysregulated in Cancer

Estimate >100 Transcription Factors Associated with Just the BAF Complex

PLATFORM & DRUGGING CAPABILITIES

PLATFORM IS POWERED BY ABILITY TO PRODUCE COMPONENTS AT SCALE

Drives Drug Discovery Pipeline with Cutting Edge Technology

PRODUCTION OF CHROMATIN REGULATORY SYSTEM COMPONENTS





	FEATURES	BENEFITS
	Surface Mapping	Characterize TF / BAF Binding Sites
	Assembly	Synthesize subcomplexes to enable drug discovery
	Affinity Screening & Validation	ASMS on full complex to yield novel degraders
	HTS	Multiple screening options with full complex
	Biophysics/SPR	Validation of novel small molecule binders

PROTEIN DEGRADER PLATFORM

CURRENT APPROACH

- A leader in developing heterobifunctional degraders for clinical evaluation in oncology
- Employing PROTAC and non-CRBN based molecular glue degradation approaches

DEGRADER CHEMICAL TOOLBOX

- Proprietary library of drug-like linkers, E3 ligase binders and potential glues
- Chemistry to rapidly identify and optimize degraders

ADVANCED MECHANISTIC CHARACTERIZATION

- Native target turnover understanding
- Cellular degradation kinetics and rates
- Structural, biochemical and cellular ternary complex characterization
- Global proteomics and ubiquitination studies
- Computational modeling of degraders
- Degradation efficacy across multiple cell types

OPTIMIZATION OF DEGRADER DRUG PROPERTIES

- Guidelines for both of oral and IV-administered degraders
- PK / PD, efficacy and safety modeling to optimize dosing and scheduling





Leadership Team, Board & Advisors

EXPERTISE ACROSS DRUG DISCOVERY, CLINICAL DEVELOPMENT AND COMMERCIALIZATION

PROVEN LEADERSHIP TEAM

ADRIAN GOTTSCHALK
President & CEO

SAM AGRESTA, M.D., M.P.H & TM
Chief Medical Officer

STEVE BELLON, PH.D.
Chief Scientific Officer

FANNY CAVALIE
Chief Strategy and Business Operations Officer

CARLOS COSTA
Chief People Officer

MICHAEL LACASCIA
Chief Legal Officer

ALLAN REINE, M.D.
Chief Financial Officer

JACQUELINE CINICOLA
VP, Regulatory Affairs

DANETTE L. DANIELS, PH.D.
VP, Protein Degrader Platform

ANDREW GERMAIN, PH.D.
VP, Legal

CHONG-HUI GU, PH.D.
VP, CMC and QA

KARIN HELLSVIK
VP, Corporate Affairs

MURPHY HENTEMANN, PH.D.
VP, Program Leadership

SCOTT INNIS
VP, Program Leadership

NICOLA MAJCHRZAK
VP, Clinical Development Operations

MARINA NELEN, PH.D.
VP, Drug Discovery

SAURABH SEWAK
VP, Corporate Development

BEN STRAIN
VP, Investor Relations & Corporate Communications

KEVIN WILSON
VP, Chemistry

INDUSTRY-LEADING BOARD OF DIRECTORS AND ADVISORS

BOARD OF DIRECTORS

DOUG COLE, M.D.
Flagship Pioneering – Board Chair; Founder

SCOTT BILLER, PH.D.
Former CSO and Strategic Advisor, Agios

SIMBA GILL, PH.D.
Evelo Biosciences, Partner at Flagship Pioneering

ADRIAN GOTTSCHALK
Foghorn President & CEO

ADAM KOPPEL, M.D., PH.D.
Bain Capital Life Sciences

THOMAS J. LYNCH, JR., M.D.
Fred Hutchinson Cancer Center

MICHAEL MENDELSOHN, M.D.
Cardurion Pharmaceuticals

B. LYNNE PARSHALL, ESQ.
Senior Strategic Advisor, Ionis Pharmaceuticals

IAN SMITH
Exec. Chair of Solid Bio., Former COO of Vertex

SCIENTIFIC & OTHER ADVISORS

CHARLES SAWYERS, M.D.
MSKCC, HHMI – SAB Chair

CRAIG PETERSON, PH.D.
Professor, UMass Medical School

GERALD CRABTREE, M.D.
Stanford, HHMI; Founder

DAVID SCHENKEIN, M.D.
General Partner, GV

TONY KOUZARIDES, PH.D.
Gurdon Institute – University of Cambridge

CIGALL KADOCH, PH.D.
Dana-Farber, Broad, HMS, HHMI; Founder